Ultragenyx Pharmaceutical | RARE - Gross Profit On Sales

Stock Price
24.65
Daily Change
0.86 3.62%
Monthly
1.86%
Yearly
-45.65%
Q1 Forecast
23.33

Ultragenyx Pharmaceutical reported $131.94M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Insmed USD 111.44M 33.36M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
Kyowa Hakko Kirin JPY 90.6B 1.95B Sep/2025
MacroGenics USD 61.25M 88.71M Sep/2025
Moderna USD 809M 791M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
PTC Therapeutics USD 187.69M 24.3M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025